In vivo protection against NMDA-induced neurodegeneration by MK-801 and nimodipine: Combined therapy and temporal course of protection

B. T. Stuiver, B. R K Douma, R. Bakker, C. Nyakas, P. G M Luiten

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Neuroprotection against excitotoxicity by a combined therapy with the N-methyl-D-aspartate (NMDA) receptor antagonist MK-801 and the L-type Ca2+ channel blocker nimodipine was examined using an in vivo rat model of NMDA-induced neurodegeneration. Attention was focused on the neuroprotective potential of this combined drug treatment before and after NMDA-exposure. NMDA was unilaterally injected in the magnocellular nucleus basalis (MBN). Neuronal damage was assessed 12 days after the NMDA-injection by measuring the reduction of cholinergic cortical fibres that originate from the MBN neurons. In controls that received no drug treatment, NMDA-exposure damaged MBN neurons such that 66% of the cholinergic terminals were lost in the ipsilateral parietal cortex. Pretreatment with a nimodipine diet (860 ppm) combined with application of MK-801 (5 mg/kg i.p.) before NMDA-exposure reduced fibre loss by 89% thereby providing a near complete neuroprotection. Combined therapy of MK-801 (5 mg/kg i.p.) and nimodipine (15 mg/kg i.p.) 8 min after NMDA-infusion reduced neuronal injury by 82%, while the same combination given 2 h after the excitotoxic treatment still yielded a 66% protection against neurotoxic damage invoked by NMDA. In conclusion, the present data show that a dual blockade of NMDA-channels and voltage-dependent calcium channels (VDCC's) up to 2 h after NMDA-exposure is able to provide a significant protection against NMDA-neurotoxicity.

Original languageEnglish
Pages (from-to)153-159
Number of pages7
JournalNeurodegeneration
Volume5
Issue number2
DOIs
Publication statusPublished - Jun 1996

Fingerprint

Nimodipine
Dizocilpine Maleate
N-Methylaspartate
Therapeutics
Cholinergic Fibers
Neurons
Parietal Lobe
Calcium Channels
N-Methyl-D-Aspartate Receptors
Pharmaceutical Preparations
Cholinergic Agents

Keywords

  • Calcium antagonists
  • Combined therapy
  • Excitotoxic
  • Neuroprotection
  • Temporal course

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology
  • Pathology and Forensic Medicine
  • Clinical Neurology

Cite this

In vivo protection against NMDA-induced neurodegeneration by MK-801 and nimodipine : Combined therapy and temporal course of protection. / Stuiver, B. T.; Douma, B. R K; Bakker, R.; Nyakas, C.; Luiten, P. G M.

In: Neurodegeneration, Vol. 5, No. 2, 06.1996, p. 153-159.

Research output: Contribution to journalArticle

@article{f90d44b8b26a4eb2aa4d8584fb7aa32e,
title = "In vivo protection against NMDA-induced neurodegeneration by MK-801 and nimodipine: Combined therapy and temporal course of protection",
abstract = "Neuroprotection against excitotoxicity by a combined therapy with the N-methyl-D-aspartate (NMDA) receptor antagonist MK-801 and the L-type Ca2+ channel blocker nimodipine was examined using an in vivo rat model of NMDA-induced neurodegeneration. Attention was focused on the neuroprotective potential of this combined drug treatment before and after NMDA-exposure. NMDA was unilaterally injected in the magnocellular nucleus basalis (MBN). Neuronal damage was assessed 12 days after the NMDA-injection by measuring the reduction of cholinergic cortical fibres that originate from the MBN neurons. In controls that received no drug treatment, NMDA-exposure damaged MBN neurons such that 66{\%} of the cholinergic terminals were lost in the ipsilateral parietal cortex. Pretreatment with a nimodipine diet (860 ppm) combined with application of MK-801 (5 mg/kg i.p.) before NMDA-exposure reduced fibre loss by 89{\%} thereby providing a near complete neuroprotection. Combined therapy of MK-801 (5 mg/kg i.p.) and nimodipine (15 mg/kg i.p.) 8 min after NMDA-infusion reduced neuronal injury by 82{\%}, while the same combination given 2 h after the excitotoxic treatment still yielded a 66{\%} protection against neurotoxic damage invoked by NMDA. In conclusion, the present data show that a dual blockade of NMDA-channels and voltage-dependent calcium channels (VDCC's) up to 2 h after NMDA-exposure is able to provide a significant protection against NMDA-neurotoxicity.",
keywords = "Calcium antagonists, Combined therapy, Excitotoxic, Neuroprotection, Temporal course",
author = "Stuiver, {B. T.} and Douma, {B. R K} and R. Bakker and C. Nyakas and Luiten, {P. G M}",
year = "1996",
month = "6",
doi = "10.1006/neur.1996.0022",
language = "English",
volume = "5",
pages = "153--159",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - In vivo protection against NMDA-induced neurodegeneration by MK-801 and nimodipine

T2 - Combined therapy and temporal course of protection

AU - Stuiver, B. T.

AU - Douma, B. R K

AU - Bakker, R.

AU - Nyakas, C.

AU - Luiten, P. G M

PY - 1996/6

Y1 - 1996/6

N2 - Neuroprotection against excitotoxicity by a combined therapy with the N-methyl-D-aspartate (NMDA) receptor antagonist MK-801 and the L-type Ca2+ channel blocker nimodipine was examined using an in vivo rat model of NMDA-induced neurodegeneration. Attention was focused on the neuroprotective potential of this combined drug treatment before and after NMDA-exposure. NMDA was unilaterally injected in the magnocellular nucleus basalis (MBN). Neuronal damage was assessed 12 days after the NMDA-injection by measuring the reduction of cholinergic cortical fibres that originate from the MBN neurons. In controls that received no drug treatment, NMDA-exposure damaged MBN neurons such that 66% of the cholinergic terminals were lost in the ipsilateral parietal cortex. Pretreatment with a nimodipine diet (860 ppm) combined with application of MK-801 (5 mg/kg i.p.) before NMDA-exposure reduced fibre loss by 89% thereby providing a near complete neuroprotection. Combined therapy of MK-801 (5 mg/kg i.p.) and nimodipine (15 mg/kg i.p.) 8 min after NMDA-infusion reduced neuronal injury by 82%, while the same combination given 2 h after the excitotoxic treatment still yielded a 66% protection against neurotoxic damage invoked by NMDA. In conclusion, the present data show that a dual blockade of NMDA-channels and voltage-dependent calcium channels (VDCC's) up to 2 h after NMDA-exposure is able to provide a significant protection against NMDA-neurotoxicity.

AB - Neuroprotection against excitotoxicity by a combined therapy with the N-methyl-D-aspartate (NMDA) receptor antagonist MK-801 and the L-type Ca2+ channel blocker nimodipine was examined using an in vivo rat model of NMDA-induced neurodegeneration. Attention was focused on the neuroprotective potential of this combined drug treatment before and after NMDA-exposure. NMDA was unilaterally injected in the magnocellular nucleus basalis (MBN). Neuronal damage was assessed 12 days after the NMDA-injection by measuring the reduction of cholinergic cortical fibres that originate from the MBN neurons. In controls that received no drug treatment, NMDA-exposure damaged MBN neurons such that 66% of the cholinergic terminals were lost in the ipsilateral parietal cortex. Pretreatment with a nimodipine diet (860 ppm) combined with application of MK-801 (5 mg/kg i.p.) before NMDA-exposure reduced fibre loss by 89% thereby providing a near complete neuroprotection. Combined therapy of MK-801 (5 mg/kg i.p.) and nimodipine (15 mg/kg i.p.) 8 min after NMDA-infusion reduced neuronal injury by 82%, while the same combination given 2 h after the excitotoxic treatment still yielded a 66% protection against neurotoxic damage invoked by NMDA. In conclusion, the present data show that a dual blockade of NMDA-channels and voltage-dependent calcium channels (VDCC's) up to 2 h after NMDA-exposure is able to provide a significant protection against NMDA-neurotoxicity.

KW - Calcium antagonists

KW - Combined therapy

KW - Excitotoxic

KW - Neuroprotection

KW - Temporal course

UR - http://www.scopus.com/inward/record.url?scp=0030175747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030175747&partnerID=8YFLogxK

U2 - 10.1006/neur.1996.0022

DO - 10.1006/neur.1996.0022

M3 - Article

C2 - 8819136

AN - SCOPUS:0030175747

VL - 5

SP - 153

EP - 159

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

IS - 2

ER -